Pharmaceuticals

VivaCel Bio Initiates Phase 3 Clinical Trial of VBI-S for the Treatment of Hypovolemic Septic Shock

bexib
By bexib 0 Min Read

The trial will enroll 40 patients across the United States who have not responded adequately to standard hypovolemic septic shock treatments and are taking vasopressor drugs.

You Might Also Like

Fitterfly launches at-home digital therapy that uses AI to analyze food images

Three biotech hotspots in the US

Driving innovation: How collaboration between medical and commercial teams is transforming the industry

Leveraging pre-approval information exchange to drive product success and patient access: Q&A with Alvana Maliqi

Study finds headache medicine may prevent acute migraine medication overuse

Share This Article
Previous Article What happened to the mixed economy?
Next Article Congress Passes Bipartisan National Flag Act
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

OJK takes over Indonesia’s crypto supervision from Bape Buti
Fintech
Cambodia introduces new regulations on the use and licensing of crypto assets
Fintech
Top 18 Fintech Events in APAC to Attend in Q1 2025
Fintech
Rakkar secures digital asset custody license in Thailand
Fintech